IT sector outlook: Demand uncertainty to prolong weakness in FY26

With demand uncertainties in the IT services industry from H2CY24 having trickled into CY2025 budgets, Kotak Institutional Equities (KIE) said, the weakness will continue in FY2026. The demand pipeline has built up well at most ERD service providers with exposure to the automotive vertical. However, it added, deferral of decision-making by German OEMs has impacted conversion. Demand outlook at other manufacturing-focused industries is also yet to improve. “We bake in a moderate demand outlook, leading to cuts to earnings estimates across companies. We retain our cautious view owing to slowing macro and weak demand outlook despite a ~14-40 per cent decline in stock prices over the past three months,” KIE report said.

ALSO READTRAI plans to limit satellite broadband spectrum permits to five years, defying Musk’s Starlink

Healthy pipeline but conversion stuck in a limbo

Per the analysis report, automobile OEMs are realigning their investments to meet evolving demand patterns. “While new platform development-related spends remain relatively resilient, OEMs are at a crossroads to either double down on electrification initiatives or channel investments toward alternate powertrains (hybrid/ICE). Auto OEMs realize the need to invest in new technologies to ensure business relevance,” the Kotak report stated. 

The pipeline, the report said, has built up to record levels across most Indian and European players, as more RFQs (Request for Quotation) are floated by clients. The uncertainty around the medium-term strategy has impacted decision-making and as a consequence, conversion into the order book. 

Kotak said that impact has been more severe for German OEMs and has percolated down to the spending outlook by these clients. “We believe spending would remain weak in H1CY25, but the recovery is likely to be gradual, resulting in a weak growth outlook for the year,” it said.

Pricing pressure might stem from increased competitive intensity for large deals

Auto OEM R&D spending growth in CY2025 will be modest, with a focus on efficiency and shifting investments to low-cost countries from nearshore locations. Kotak Equities said that ESPs with strong embedded engineering and offshore capabilities could benefit from large deals, but intense competition and cost pressures may impact pricing in new contracts.

Overview on weak demand outlook

Kotak Equities lowered revenue growth estimates for KPIT, TELX, and TTL for FY2026-27E due to delayed pipeline conversion and JLR exposure,

 » Read More

Related Articles

Zydus Lifesciences – Will it succeed in aggressively moving up the value chain?

By Amriteshwar Mathur Zydus Lifesciences is attempting to move up the value chain in the global pharma industry with its expanding focus on the medical technology segment. As part of the above strategy, Zydus Lifesciences has made a foray in the higher margin orthopedic products segment with an acquisition of 85.6% stake in France-based Amplitude

Two chemical stocks indicating strength and reversal

By Kiran Jani The chemical sector, which has been on a downward trend for the past five months is finally showing signs of a recovery. With prices stabilising and the broader market improving, some stocks are showing potential for a turnaround. HEG and Graphite have formed potential reversal patterns, indicating possible opportunities for traders and

Three auto stocks potentially at bargain buying point

The market has been in a corrective phase for the seventh consecutive month, with many stocks taking a significant dip of 20-40%. After a period of stellar returns between 2020 and 2024, investor expectations were sky-high, but the recent downturn has led to many losing interest in the markets. While these dips have been challenging

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Zydus Lifesciences – Will it succeed in aggressively moving up the value chain?

By Amriteshwar Mathur Zydus Lifesciences is attempting to move up the value chain in the global pharma industry with its expanding focus on the medical technology segment. As part of the above strategy, Zydus Lifesciences has made a foray in the higher margin orthopedic products segment with an acquisition of 85.6% stake in France-based Amplitude

Two chemical stocks indicating strength and reversal

By Kiran Jani The chemical sector, which has been on a downward trend for the past five months is finally showing signs of a recovery. With prices stabilising and the broader market improving, some stocks are showing potential for a turnaround. HEG and Graphite have formed potential reversal patterns, indicating possible opportunities for traders and

Three auto stocks potentially at bargain buying point

The market has been in a corrective phase for the seventh consecutive month, with many stocks taking a significant dip of 20-40%. After a period of stellar returns between 2020 and 2024, investor expectations were sky-high, but the recent downturn has led to many losing interest in the markets. While these dips have been challenging

Is your FD really safe? Know insurance coverage for your deposits with IndusInd and other banks

IndusInd Bank is in the news this week as its stock crashed to a 52-week low (on March 11, 2025) due to an accounting error linked to forex derivative transactions. However, the stock recovered slightly the next day. This financial mess, which might not directly harm ordinary depositors, has once again drawn attention to bank

Baba Ramdev’s Patanjali Ayurved enters insurance sector with majority stake in Magma General Insurance

Baba Ramdev-owned Patanjali Ayurved has expanded its business footprint by acquiring a majority stake in Magma General Insurance. This strategic move marks Patanjali’s entry into the competitive general insurance sector, further diversifying its portfolio beyond its established Ayurvedic, wellness, and consumer goods offerings, reports CNBC TV18. Following the acquisition, Patanjali Ayurved will become the promoter